Inovio Pharmaceuticals Return on Equity

Inovio Pharmaceuticals (GBM.F) currently reports a ROE of -1942959.72%. That is below the Industrials sector average of 35.62%. Use the charts on this page to explore Inovio Pharmaceuticals's ROE history and peer comparisons.

Inovio Pharmaceuticals's ROE of -1942959.72% is lower than the Industrials sector average of 35.62%. That is roughly 5454607.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Inovio Pharmaceuticals's current -1942959.72% should be judged against Industrials norms (sector average: 35.62%) and against GBM.F's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -1942959.72%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Industrials average is 35.62%. From there, open related valuation or income-statement pages for Inovio Pharmaceuticals, and consider following GBM.F for alerts when major investors trade the stock.

Inovio Pharmaceuticals is classified in the Industrials sector. On ROE, it currently shows -1942959.72% versus a sector average near 35.62%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing GBM.F with unrelated industries.